Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial

201448 citationsJournal Articlebronze Open Access

Authors

This study could not prove the efficacy of octreotide LAR in the prevention of CID.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 32, Issue 10, pp. 1006-1011

Field-Weighted Citation Impact: 2.39